{"id":380924,"date":"2020-11-13T09:59:57","date_gmt":"2020-11-13T14:59:57","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=380924"},"modified":"2020-11-13T09:59:57","modified_gmt":"2020-11-13T14:59:57","slug":"bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/","title":{"rendered":"BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Nov.  13, 2020  (GLOBE NEWSWIRE) &#8212; Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020. If you wish to serve as lead plaintiff, you must move the Court before the <strong>NOVEMBER <\/strong><strong>24<\/strong><strong>, 2020<\/strong><strong> DEADLINE<\/strong><strong>.<\/strong><\/p>\n<p>To join the class action, go to\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_W5cy9Lnu8iDH7Px414Spti0yybcsjsDLNFGzek4fyTp_Sn2cYQ7-8OTwkTruPQ7cYQaXdEnsznm2V6498FA3k5luupU0ezoNGPTsOsL6GdJO3mLMbIgtrecfOR0i6y-BSii78TW8NAwIP3wNnorhyIOdxTgzag9_3rw6I70DpuR0ATReEmR4ghkL1roeJUFruoXJg7UpkglQXXLwdLMa-Y2ryA7wAolt6dMAI0M2w_WqoxycWXfyw8xPUW02m7BrWuwDXpMst4K6yl8WE3fWA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/zhanginvestorlaw.com\/join-action-form\/?slug=biomarin-pharmaceutical-inc&amp;id=2428<\/a> or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Bzr5wIBANA9V9-5lXJijYrfBYKHqmRWWssfDymWB41eeBZPrHhRnFfGB_3oOXTm0oaihAzodY8_mK5C0Y4UbSY5oPHTSCvA_tzwT6oTUB2U=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@zhanginvestorlaw.com<\/a>\u00a0for information on the class action.<\/p>\n<p>\u5982\u679c\u60a8\u60f3\u52a0\u5165\u8fd9\u4e2a\u96c6\u4f53\u8bc9\u8bbc\u6848\uff0c\u8bf7\u5728\u8fd9\u91cc\u63d0\u4ea4\u60a8\u7684\u4fe1\u606f\u3002<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_W5cy9Lnu8iDH7Px414Spti0yybcsjsDLNFGzek4fyTp_Sn2cYQ7-8OTwkTruPQ7cYQaXdEnsznm2V6498FA3k5luupU0ezoNGPTsOsL6GdJO3mLMbIgtrecfOR0i6y-Dd-XX_tjkdrm92-rUSoheF1fhxnJTSH2AX0zrgWHONflXd9sUg1YbR_sWfo_r6I644F-JVWKde6Wf82nyrYx_kCCF4sXwN7rkkZsGDLUQh72Tn06CZUpRuTHPLFopCkhe2kJKzJayfidtoRE2EYQwg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">http:\/\/zhanginvestorlaw.com\/join-action-form\/?slug=biomarin-pharmaceutical-inc&amp;id=2428<\/a><\/p>\n<p>If you wish to serve as lead plaintiff, you must move the Court before the <strong>NOVEMBER <\/strong><strong>24<\/strong><strong>, 20<\/strong><strong>20<\/strong><strong> DEADLINE<\/strong><strong>.<\/strong>\u00a0 A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.\u00a0<\/p>\n<p>According to the lawsuit, defendants throughout the Class Period made false and\/or misleading statements and\/or failed to disclose, among other things:\u00a0 differences between the Phase 1\/2 and Phase 3 study of valoctocogene roxaparvovec limited the reliability of the Phase 1\/2 study to support valoctocogene roxaparvovec\u2019s durability of effect; as a result, it was foreseeable that the U.S. Food and Drug Administration would not approve the Biologics License Application for valoctocogene roxaparvovec without additional data; and as a result, the Company\u2019s public statements were materially false and misleading at all relevant times.<\/p>\n<p>Lead plaintiff status is not required to seek compensation.\u00a0 You may retain counsel of your choice.\u00a0 You may remain an absent class member and take no action at this time.<\/p>\n<p>Zhang Investor Law represents investors worldwide. Attorney Advertising. Prior results do not guarantee similar outcomes.<\/p>\n<p>Zhang Investor Law P.C.<br \/>99 Wall Street, Suite 232<br \/>New York, New York 10005<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Bzr5wIBANA9V9-5lXJijYrfBYKHqmRWWssfDymWB41f3U245PcsUAxoo3I5lmNLL2-lsZjoMG1QkfbT-rUsSnMvtTnmd6mXYoaUTV6KofpU=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@zhanginvestorlaw.com<\/a><br \/>tel: (800) 991-3756<\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTg1MCMzODI2NTQxIzUwMDA1MzY0MQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/f252956b-86ff-4b02-889f-3e89c68351ee\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020. If you wish to serve as lead plaintiff, you must move the Court before the NOVEMBER 24, 2020 DEADLINE. To join the class action, go to\u00a0http:\/\/zhanginvestorlaw.com\/join-action-form\/?slug=biomarin-pharmaceutical-inc&amp;id=2428 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email\u00a0info@zhanginvestorlaw.com\u00a0for information on the class action. \u5982\u679c\u60a8\u60f3\u52a0\u5165\u8fd9\u4e2a\u96c6\u4f53\u8bc9\u8bbc\u6848\uff0c\u8bf7\u5728\u8fd9\u91cc\u63d0\u4ea4\u60a8\u7684\u4fe1\u606f\u3002http:\/\/zhanginvestorlaw.com\/join-action-form\/?slug=biomarin-pharmaceutical-inc&amp;id=2428 If you wish to serve as lead plaintiff, you must move the Court before the NOVEMBER 24, 2020 DEADLINE.\u00a0 A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.\u00a0 According to the lawsuit, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-380924","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020. If you wish to serve as lead plaintiff, you must move the Court before the NOVEMBER 24, 2020 DEADLINE. To join the class action, go to\u00a0http:\/\/zhanginvestorlaw.com\/join-action-form\/?slug=biomarin-pharmaceutical-inc&amp;id=2428 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email\u00a0info@zhanginvestorlaw.com\u00a0for information on the class action. \u5982\u679c\u60a8\u60f3\u52a0\u5165\u8fd9\u4e2a\u96c6\u4f53\u8bc9\u8bbc\u6848\uff0c\u8bf7\u5728\u8fd9\u91cc\u63d0\u4ea4\u60a8\u7684\u4fe1\u606f\u3002http:\/\/zhanginvestorlaw.com\/join-action-form\/?slug=biomarin-pharmaceutical-inc&amp;id=2428 If you wish to serve as lead plaintiff, you must move the Court before the NOVEMBER 24, 2020 DEADLINE.\u00a0 A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.\u00a0 According to the lawsuit, &hellip; Continue reading &quot;BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-13T14:59:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTg1MCMzODI2NTQxIzUwMDA1MzY0MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN\",\"datePublished\":\"2020-11-13T14:59:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/\"},\"wordCount\":302,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTg1MCMzODI2NTQxIzUwMDA1MzY0MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/\",\"name\":\"BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTg1MCMzODI2NTQxIzUwMDA1MzY0MQ==\",\"datePublished\":\"2020-11-13T14:59:57+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTg1MCMzODI2NTQxIzUwMDA1MzY0MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4NTg1MCMzODI2NTQxIzUwMDA1MzY0MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/","og_locale":"en_US","og_type":"article","og_title":"BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN - Market Newsdesk","og_description":"NEW YORK, Nov. 13, 2020 (GLOBE NEWSWIRE) &#8212; Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from February 28, 2020 through August 18, 2020. If you wish to serve as lead plaintiff, you must move the Court before the NOVEMBER 24, 2020 DEADLINE. To join the class action, go to\u00a0http:\/\/zhanginvestorlaw.com\/join-action-form\/?slug=biomarin-pharmaceutical-inc&amp;id=2428 or call Sophie Zhang, Esq. toll-free at 800-991-3756 or email\u00a0info@zhanginvestorlaw.com\u00a0for information on the class action. \u5982\u679c\u60a8\u60f3\u52a0\u5165\u8fd9\u4e2a\u96c6\u4f53\u8bc9\u8bbc\u6848\uff0c\u8bf7\u5728\u8fd9\u91cc\u63d0\u4ea4\u60a8\u7684\u4fe1\u606f\u3002http:\/\/zhanginvestorlaw.com\/join-action-form\/?slug=biomarin-pharmaceutical-inc&amp;id=2428 If you wish to serve as lead plaintiff, you must move the Court before the NOVEMBER 24, 2020 DEADLINE.\u00a0 A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.\u00a0 According to the lawsuit, &hellip; Continue reading \"BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-13T14:59:57+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTg1MCMzODI2NTQxIzUwMDA1MzY0MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN","datePublished":"2020-11-13T14:59:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/"},"wordCount":302,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTg1MCMzODI2NTQxIzUwMDA1MzY0MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/","name":"BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTg1MCMzODI2NTQxIzUwMDA1MzY0MQ==","datePublished":"2020-11-13T14:59:57+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTg1MCMzODI2NTQxIzUwMDA1MzY0MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4NTg1MCMzODI2NTQxIzUwMDA1MzY0MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bmrn-upcoming-deadline-zhang-investor-law-alerts-investors-to-imminent-deadline-in-securities-class-action-lawsuit-against-biomarin-pharmaceutical-inc-bmrn\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BMRN UPCOMING DEADLINE: Zhang Investor Law Alerts Investors to Imminent Deadline in Securities Class Action Lawsuit Against\u00a0\u00a0BioMarin Pharmaceutical Inc. \u2013 BMRN"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380924","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=380924"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/380924\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=380924"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=380924"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=380924"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}